SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Veracyte,
Inc. (NASDAQ: VCYT) today announced that the Centers for Medicare &
Medicaid Services (CMS) published preliminary 2018 rates for clinical
diagnostic laboratory tests. The reimbursement rate for the Afirma
Genomic Classifier (code 81545) is expected to increase from $3,220 to
$3,600 for calendar year 2018. The preliminary rate is based on the
median of private payer payments submitted by Veracyte as part of the
market-based payment reforms mandated through the Protecting Access to
Medicare Act of 2014 (PAMA). The CMS plans to finalize the rates in
November 2017, following a public comment period, and the new rates are
scheduled to become effective January 1, 2018.
"We believe this new rate for the Afirma classifier reflects the value
our test delivers to physicians and patients by reducing unnecessary
thyroid surgeries and associated healthcare costs," stated Bonnie
Anderson, chairman and chief executive officer of Veracyte. "We are
pleased that CMS is moving forward with implementation of PAMA following
the original delays to ensure smooth data submission."
About PAMA
On June 17, 2016, CMS released a final rule implementing Section 216(a)
of the Protecting Access to Medicare Act of 2014 (PAMA), requiring
laboratories performing clinical diagnostic laboratory tests to report
the amounts paid by private insurers for laboratory tests. CMS indicated
that it would calculate the weighted median of these private insurer
rates to determine Medicare payment rates for laboratory tests paid
under the Clinical Laboratory Fee Schedule (CLFS) beginning January 1,
2018. (CMS extended the original date of January 1, 2017 to provide time
for laboratories to establish necessary reporting infrastructure.)
Laboratories were required to collect private payer data from January 1,
2016 through June 30, 2016 and report it to CMS by May 30, 2017. These
rates were used to calculate Medicare payment rates for advanced
laboratory diagnostic tests (ADLTs). Preliminary rates were published on
September 22, 2017. CMS plans to finalize the rates in November 2017,
following a public comment period, and the new rates are scheduled to
become effective January 1, 2018.
About Veracyte
Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is
fundamentally improving patient care by resolving diagnostic uncertainty
with evidence that is trustworthy and actionable. The company's products
uniquely combine genomic technology, clinical science and machine
learning to provide answers that give physicians and patients a clear
path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic
classifiers, which are transforming the diagnosis of thyroid cancer,
lung cancer and idiopathic pulmonary fibrosis and collectively target a
$2 billion market opportunity. Veracyte is based in South San Francisco,
California. For more information, please visit www.veracyte.com
and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as:
"believe," "plans," "preliminary," and similar references to future
periods. Forward-looking statements include, among others, the amount of
the rate, the timing of the proposed increase, and the company's belief
that the new rates reflect the value of the company's test to physicians
and payers. Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on our
current beliefs, expectations and assumptions regarding the future of
our business, future plans and strategies, anticipated events and
trends, the economy and other future conditions. Forward-looking
statements involve risks and uncertainties, which could cause actual
results to differ materially, and reported results should not be
considered as an indication of future performance. These risks and
uncertainties include, but are not limited to: the final reimbursement
rate for our test, our ability to successfully achieve and maintain
adoption of and reimbursement for our products; and other risks set
forth in the company's filings with the Securities and Exchange
Commission, including the risks set forth in the company's Quarterly
Report on Form 10-Q for the quarter ended June 30, 2017. These
forward-looking statements speak only as of the date hereof
and Veracyte specifically disclaims any obligation to update these
forward-looking statements.
Veracyte, and the Veracyte logo are trademarks of Veracyte, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170925005515/en/
Veracyte, Inc.
Media:
Tracy Morris, 650-380-4413
tracy.morris@veracyte.com
Investors:
Jackie
Cossmon, 650-243-6371
jackie@veracyte.com
Source: Veracyte, Inc.
News Provided by Acquire Media